Immunotherapy
Study identifies SLAMF6 as a self-activating brake on anti-cancer T cells, pointing to a new immunotherapy target
AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨
A research team led by Université de Montréal immunologist André Veillette reports that the immune receptor SLAMF6 can inhibit T cells by activating through interactions on the T cell surface itself, a mechanism the authors say could help explain why some patients fail to respond—or later stop responding—to checkpoint-based cancer immunotherapies. In the same study, the researchers describe monoclonal antibodies designed to block SLAMF6’s self-interaction, which boosted T-cell activity in laboratory tests and strengthened anti-tumor responses in mouse experiments.
A protein called NFIL3 has been identified as a key factor in reducing the long-term performance of CAR T cells used in cancer treatment. Researchers showed that disabling this protein allows the engineered cells to remain active longer and fight tumors more effectively in laboratory models.
AI에 의해 보고됨 사실 확인됨
Researchers at McGill University report a drug-based method to temporarily enhance natural killer (NK) cells—an immune cell type—by inhibiting two proteins, improving the cells’ ability to attack several aggressive cancers in preclinical experiments.
Scientists at KAIST in South Korea have developed a novel therapy that transforms a tumor's own immune cells into potent cancer fighters directly inside the body. By injecting lipid nanoparticles into tumors, the treatment reprograms macrophages to produce cancer-recognizing proteins, overcoming barriers in solid tumor treatment. Early animal studies show promising reductions in tumor growth.
AI에 의해 보고됨
Researchers in Japan have uncovered how cancer cells use tiny vesicles to spread the immune-suppressing protein PD-L1, explaining why immunotherapy often fails. A protein called UBL3 directs this process, but common statins can disrupt it, potentially boosting treatment effectiveness. The findings, from patient samples and lab tests, suggest a simple way to improve outcomes for lung cancer patients.
Cold Spring Harbor Laboratory researchers report that engineered anti-uPAR CAR T cells cleared senescence-linked cells in mice, improving intestinal regeneration, reducing inflammation and strengthening gut barrier function. The approach also aided recovery from radiation-related intestinal injury and showed regenerative signals in experiments using human intestinal and colorectal cells, raising the possibility of future clinical trials.
AI에 의해 보고됨
Researchers from MIT and Stanford University have developed multifunctional molecules called AbLecs to block sugar-based immune checkpoints on cancer cells. This approach aims to enhance immunotherapy by allowing immune cells to better target tumors. Early tests in cells and mice show promising results in boosting anti-tumor responses.
Stiffening cancer cells boosts car t-cell therapy in mice
2026년 03월 20일 03시 50분Virus therapy enhances immune attack on glioblastoma
2026년 03월 16일 16시 23분Engineered antibody shrinks tumors body-wide in early cancer trial
2026년 02월 19일 00시 03분Chinese team reports scalable way to generate large batches of engineered NK cells from cord-blood stem cells
2026년 02월 06일 21시 16분Study details “good” and “bad” regulatory T cells in colorectal cancer, pointing to more selective immunotherapy targets
2026년 01월 20일 03시 55분UBC researchers show how to reliably generate helper T cells from stem cells by tuning Notch signaling
2026년 01월 16일 22시 24분Vitamin A molecule helps cancer evade immune detection
2026년 01월 15일 14시 16분Northwestern antibody targets pancreatic cancer's immune evasion
2026년 01월 11일 01시 35분KAIST injection reprograms tumor macrophages into cancer fighters
2026년 01월 09일 12시 54분Scientists develop four-pronged antibodies to enhance immune response against cancer